Aurinia Pharmaceuticals Inc (AUPH)
4.905
+0.04
(+0.72%)
USD |
NASDAQ |
Apr 26, 16:00
4.905
0.00 (0.00%)
After-Hours: 17:56
Aurinia Pharmaceuticals Cash from Financing (TTM): -5.13M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.13M |
| September 30, 2023 | 1.135M |
| June 30, 2023 | 3.467M |
| March 31, 2023 | 3.667M |
| December 31, 2022 | 2.433M |
| September 30, 2022 | 207.47M |
| June 30, 2022 | 216.55M |
| March 31, 2022 | 216.49M |
| December 31, 2021 | 221.11M |
| September 30, 2021 | 16.63M |
| June 30, 2021 | 196.81M |
| March 31, 2021 | 196.48M |
| December 31, 2020 | 194.38M |
| September 30, 2020 | 390.05M |
| June 30, 2020 | 215.64M |
| March 31, 2020 | 215.12M |
| December 31, 2019 | 243.85M |
| September 30, 2019 | 47.55M |
| June 30, 2019 | 32.71M |
| March 31, 2019 | 35.66M |
| December 31, 2018 | 4.014M |
| September 30, 2018 | 3.457M |
| June 30, 2018 | 4.692M |
| March 31, 2018 | 2.972M |
| December 31, 2017 | 175.15M |
| Date | Value |
|---|---|
| September 30, 2017 | 203.64M |
| June 30, 2017 | 209.83M |
| March 31, 2017 | 214.80M |
| December 31, 2016 | 42.62M |
| September 30, 2016 | 14.08M |
| June 30, 2016 | 6.696M |
| March 31, 2016 | 0.47M |
| December 31, 2015 | 0.839M |
| September 30, 2015 | 1.381M |
| June 30, 2015 | 1.802M |
| March 31, 2015 | 1.422M |
| December 31, 2014 | 47.89M |
| September 30, 2014 | 47.34M |
| June 30, 2014 | 52.39M |
| March 31, 2014 | 53.22M |
| December 31, 2013 | 6.375M |
| September 30, 2013 | 7.131M |
| June 30, 2013 | 1.592M |
| March 31, 2013 | 0.7197M |
| December 31, 2012 | 0.7167M |
| September 30, 2012 | -0.0084M |
| June 30, 2012 | -0.1577M |
| March 31, 2012 | -0.1386M |
| December 31, 2011 | 2.282M |
| September 30, 2011 | 2.324M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-5.13M
Minimum
Dec 2023
390.05M
Maximum
Sep 2020
137.71M
Average
196.48M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
| Lexaria Bioscience Corp | 6.862M |
| Acasti Pharma Inc | 7.359M |
| Edesa Biotech Inc | 2.224M |
| Xenon Pharmaceuticals Inc | 353.52M |
| ESSA Pharma Inc | 0.1129M |